On 3/31/2017, Shares of Yum China Holdings, Inc (NYSE:YUMC) closed at $27.20 in last trading day. After noting the initial trading entry at $26.50, it reached to a day’s high of $27.23 and moved to a day’s low of $26.34. The recent daily volume was 3.29 million as contrast to it’s an average volume of 2.39 million.
The last close of the Yum China Holdings, Inc stock reflects that it traded up +1.79% from its 50-day moving average of $26.72. The stock traded above +1.73% to its 200-day MA of $26.74. Furthermore, it moved lower -10.44% from its 52-week high of $30.37 and +14.33% up from $23.79, which is 52-week low of the stock.
Yum China Holdings, Inc.’s (YUMC) moved with shift of 4.06% in the past week. Over the last three months, the shares of the company have changed 4.62% . The stock currently has Monthly Volatility of 1.80% and Weekly Volatility of 1.80%.
Yum China Holdings Inc is a restaurant company in China. The Company’s restaurant base consists of China’s restaurant brands, including KFC, Pizza Hut Casual Dining, Pizza Hut Home Service, East Dawning and Little Sheep.
Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) finalized the last transaction at value of $1.51, with a daily change of -0.66% or -0.01 points. The company maintained volume of 687.75 thousand shares. In past trading day, the stock hit the maximum price of $1.55 and touched to minimum value of $1.45. It has a market cap of $ 84.27M.
As of last trade close, the stock is trading downside -31.98% from its one year high of $2.22 and moved +75.58% upward from $0.86, which is one year low of the stock.
The stock traded above +6.77% from its 50-day moving average of $1.41. Furthermore, the stock moved up +23.77% to its 200-day MA of $ 1.22.
During the last month, Actinium Pharmaceuticals, Inc.’s (ATNM) has changed 13.53% and performed 13.53% over the last 6 months. The mean rating score for this stock is at 1.70. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 8.36% in recent month and observed Weekly Volatility of 7.24%.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company’s targeted radio immunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213, and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical product candidate is Iomab-B that is in Phase 3 clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase 1/2 clinical trials for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial. Actinium Pharmaceutical, Inc. was founded in 2000 and is headquartered in New York, New York.